Company news

Share this article:

Drug developer Depomed said it would cut about 25% of its workforce after its lead drug candidate, Gabapentin GR, failed in a late-stage clinical trial. The company had 105 full-time employees as of Dec. 31, according to a filing with the Securities and Exchange Commission.


Forest Laboratories and Microbia announced that they have entered into co-development and co-marketing deal valued at up to $330 million for Microbia's first-in-class compound linaclotide, currently being investigated for the treatment of constipation-predominant irritable bowel syndrome, chronic constipation and other gastrointestinal disorders.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.